ArticleCancer innovation2026
Global, Population and Genetic Evidence on the Relationships Between Immune-Mediated Inflammatory Disease and Cancer Risk.
Article in Cancer innovation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global, Population and Genetic Evidence on the Relationships Between Immune-Mediated Inflammatory Disease and Cancer Risk.Cancer innovation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune-mediated inflammatory disease (IMID) and cancer share underlying mechanisms. We aimed to comprehensively evaluate the associations between IMIDs and cancers from global, population and genetic perspectives. Methods: A triangulation framework was employed to assess the association between IMIDs and cancers, using the Global Burden of Disease Study (2012-2021) to analyse six IMIDs and 33 cancers. The UK Biobank (UKBB) prospective cohort was subsequently used to validate these associations, with hazard ratios (HRs) and 95% confidence intervals (CIs) estimated by Cox proportional hazards models. Causal inference based on genetic instruments was performed in the FinnGen and UKBB to assess the potential causal effects between IMIDs and cancers. Results: IMIDs were positively associated with the occurrence of cancers from a global perspective. Moreover, 170 specific IMID-cancer pairs revealed statistically significant associations. A total of 20 pairs of specific IMID-cancer associations were further confirmed in the UKBB cohort. Among these, the five most pronounced associations included atopic dermatitis with Hodgkin lymphoma (HR = 12.56, 95% CI: 1.76-89.59), with ovarian cancer (HR = 5.65, 95% CI: 1.41-22.65) and with non-Hodgkin lymphoma (HR = 5.11, 95% CI: 1.91-13.63); rheumatoid arthritis with Hodgkin lymphoma (HR = 3.85, 95% CI: 1.11-13.32); and psoriasis with Hodgkin lymphoma (HR = 3.43, 95% CI: 1.69-6.96). Additionally, a positive causal association between rheumatoid arthritis and Hodgkin lymphoma (inverse variance weighted OR = 1.31, 95% CI: 1.10-1.57) was observed. Conclusions: This study provides comprehensive evidence of the relationships between IMIDs and cancers from global, population and genetic perspectives and identifies 20 pairs of specific IMID-cancer associations, thereby contributing to advancements in cancer prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.